Episode Details

It's In The News - a look at the top diabetes stories and headlines happening now!

Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

Episode transcript:

fall Detroit and Seattle.

Okay.. our top story this week:

XX

The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D.

https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html

XX

Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.

The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications.

You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA.

transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/

XX

New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use.

Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%.

The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia.

XX

A new c